Finance

Lists
MVR0:FRA
Medivir AB
€0.15
+11.66%
(+0.016) 1D
Sep 4, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for MVR0...
Open
€0.13
High
€0.15
Low
€0.13
Mkt. cap
1.17B
Avg. vol.
0.00
Volume
0.00
52-wk high
€0.26
52-wk low
€0.00
No. of employees
6
Open
€0.13
High
€0.15
Low
€0.13
Mkt. cap
1.17B
Avg. vol.
0.00
Volume
0.00
52-wk high
€0.26
52-wk low
€0.00
No. of employees
6
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides. Medivir is listed on the Nasdaq Stockholm Mid Cap List. In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB
CEOChristine Lind
Employees6
Founded1988
Headquarters-
SectorBiotechnology
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.00M
5.51M
1.10M
1.20M
Cost of goods sold
8.10M
10.21M
4.50M
17.90M
Cost of revenue
8.10M
10.21M
4.50M
17.90M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.80M
7.16M
5.50M
4.30M
Operating expense
6.50M
37.66M
6.20M
4.50M
Total operating expenses
14.60M
47.88M
10.70M
22.40M
Operating income
-13.60M
-42.37M
-9.60M
-21.20M
Other non operating income
-
-500.00K
200.00K
-
EBT including unusual items
-14.60M
-43.20M
-9.40M
-20.10M
EBT excluding unusual items
-14.60M
-43.77M
-9.40M
-20.10M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-7.00K
-
200.00K
Net income
-14.60M
-43.20M
-9.40M
-20.10M
Net profit margin
-1,460.00%
-784.60%
-854.55%
-1,675.00%
Earnings per share
-0.13
-
-
-
Interest and investment income
-
41.00K
-
1.10M
Interest expense
-1.00M
-1.31M
-
-
Net interest expenses
-1.00M
-1.27M
-
1.10M
Depreciation and amortization charges
700.00K
30.51M
700.00K
-
EBITDA
-12.90M
-11.87M
-8.90M
-20.90M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google apps